Developing new drugs to treat resistant prostate cancer
Targeting chemoresistant prostate cancer with novel EED inhibitors
This study is looking for new ways to help men with advanced prostate cancer who aren't responding to the usual chemotherapy by testing new compounds that might make the treatment work better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Clark Atlanta University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11191486 on NIH RePORTER |
What this research studies
This research focuses on overcoming resistance to docetaxel, the standard chemotherapy for advanced prostate cancer, which often becomes ineffective. The team will design and test new chemical compounds that inhibit a specific protein interaction believed to help cancer cells survive treatment. They will evaluate these compounds in laboratory models to determine their effectiveness and safety. The goal is to identify promising candidates that could lead to new therapies for patients with chemoresistant prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with metastatic castration-resistant prostate cancer who have developed resistance to standard chemotherapy.
Not a fit: Patients with early-stage prostate cancer or those who have not undergone chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with advanced prostate cancer who currently have limited effective therapies.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in cancer treatment, suggesting that this approach could be effective.
Where this research is happening
Atlanta, United States
- Clark Atlanta University — Atlanta, United States (Active)
Researchers
- Principal investigator: Wu, Daqing — Clark Atlanta University
- Study coordinator: Wu, Daqing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.